

October 27, 2021

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 540737

Dear Sir(s)/Ma'am,

Sub: Outcome of Board Meeting held on October 27, 2021.

With reference to the captioned subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., October 27, 2021 has inter alia considered and approved the Unaudited Standalone and Consolidated financial results for the quarter and half year ended on September 30, 2021 (enclosed herewith).

The Meeting of the Board of Directors of the Company commenced at 9:15 a.m. and concluded at 10:15 a.m.

You are requested to take the same on your record.

Thanking you,

Yours faithfully,

For Shree Ganesh Remedies Limited

Sunny Narwani
Company Secretary

Encl.: As above



RUSHIK J PATEL & CO.

CHARTERED ACCOUNTANT

Address: 2c to 2g, 2nd Floor, Resham Bhavan, Nr. Param Doctor House, Lal Darwaja, Surat
Email: mr.rushik@ymail.com Mo. No.8866288229

Independent Auditors' Review Report

ALL AMOUNTS IN INDIAN RUPEES (₹), IN LACS EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

To,
The Board Of Directors,
M/s Shree Ganesh Remedies Limited

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of M/s Shree Ganesh Remedies Limited ("the Company") for the period ended on 30th September 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section -133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rushik J Patel & Co.
Chartered Accountants

Rushik J Patel
Proprietor
Membership No.148969
F.R.No.135751W



Date: 27th October 2021
UDIN 21148969AAAAEI3019

STATEMENT OF STANDALONE FINANCIAL STATEMENTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER 2021

ALL AMOUNTS IN LAKHS (₹), EXCEPT EPS

Particulars	Sr. No	Quarter Ended			Half year ended		Annual
		30th Sep 2021	30th June 2021	30th Sept 2020	30th Sept 2021	30th Sept 2020	31st Mar 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
INCOME							
Revenue from operations	I	1,696.94	1,263.26	1,152.33	2,960.20	2,044.77	4,908.23
Other Income	II	43.98	110.83	45.41	154.81	140.88	209.43
Total Income (I+II)	III	1,740.92	1,374.09	1,197.74	3,115.01	2,185.65	5,117.66
EXPENSES							
Cost of Material Consumed	IV	892.11	760.27	558.99	1,652.37	1,008.85	2,598.56
Purchase of Stock in trade		Nil	Nil	Nil	Nil	Nil	Nil
Changes in inventories of finished goods/ WIP		(0.12)	(143.41)	(166.69)	(143.53)	(87.08)	(396.73)
Employee Benefit Expense		106.03	101.05	98.48	207.08	175.66	384.69
Finance Costs		2.76	6.97	1.15	9.73	3.48	6.77
Depreciation and Amortisations		95.39	81.53	63.84	176.92	127.68	272.54
Other Expenses		254.46	239.79	240.77	494.24	414.62	956.89
Total Expenses		1,350.62	1,046.20	796.53	2,396.82	1,643.21	3,822.71
Profit before exceptional, Extraordinary Item and tax (III - IV)	V	390.29	327.89	401.21	718.19	542.44	1,294.95
Exceptional Items	VI	Nil	Nil	Nil	Nil	Nil	Nil
Profit before Extraordinary Item and tax (V - VI)	VII	390.29	327.89	401.21	718.19	542.44	1,294.95
Extraordinary Items	VIII	Nil	Nil	Nil	Nil	Nil	Nil
Profit before tax (VII - VIII)	IX	390.29	327.89	401.21	718.19	542.44	1,294.95
Tax Expenses	X						
Current Tax		89.84	94.35	85.54	184.19	141.35	323.16
Adjustment of Tax Related to Earlier Periods		Nil	Nil	Nil	Nil	Nil	Nil
Deferred Tax		(1.40)	(0.27)	6.22	(1.67)	6.22	(3.63)
Profit/(loss) from continuing operations (IX - X)	XI	301.85	233.82	309.45	535.67	394.87	975.42
DISCONTINUING OPERATIONS							
Profit/(loss) from discontinuing operations before tax	XII	Nil	Nil	Nil	Nil	Nil	Nil
Tax expense of discontinuing operations	XIII	Nil	Nil	Nil	Nil	Nil	Nil
Profit/(loss) from discontinuing operations after tax (XII - XIII)	XIV	Nil	Nil	Nil	Nil	Nil	Nil
TOTAL OPERATIONS							
Profit (Loss) for the period (XI + XIV)	XV	301.85	233.82	309.45	535.67	394.87	975.42
OTHER COMPREHENSIVE INCOME							
Income relating to Item that will not be classified to profit and loss		Nil	Nil	Nil	Nil	Nil	Nil
Income relating to Item that will be classified to profit and loss		Nil	Nil	Nil	Nil	Nil	Nil
Total Comprehensive Income for the period		301.85	233.82	309.45	535.67	394.87	975.42
Paid Up Equity Share Capital (Face Value Rs.10 each)		1,000.64	1,000.64	1,000.64	1,000.64	1,000.64	1,000.64
Other Equity Excluding Revaluation Reserves		Nil	Nil	Nil	Nil	Nil	3,999.67
Earning Per Share for Continuing operation							
Basic - Par Value Rs. 10		3.02	2.34	3.09	5.35	3.95	9.75
Diluted - Par Value Rs.10		3.02	2.34	3.09	5.35	3.95	9.75

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806
Ankleshwar
27th October 2021



Head Office (Unit-1) :
Plot No. 6011-12, GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661
GSTIN : 24ABACS1471R1Z0 (Zero)

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
(Formally known as Ashok Pharma Chem)



www.ganeshremedies.com
WEBSITE

contact@ganeshremedies.com

EMAIL

Balance Sheet OF STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED

ALL AMOUNTS IN LAKHS, EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30TH SEPTEMBER 2021 (Unaudited)	AS AT 31 MARCH 2021 (Audited)
ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipments	2,552.54	1,824.64
(b) Capital work in progress	85.88	204.83
(c) Investment property	Nil	Nil
(d) Goodwill	Nil	Nil
(e) Other Intangible Assets	49.67	60.49
(f) Intangible Assets under development	Nil	Nil
(g) Biological Assets other than bearer Plant	Nil	Nil
(h) Financial Assets		
(i) Investments	8.74	7.00
(iii) Loans	161.53	153.75
(j) Deferred Tax Assets (Net)	Nil	Nil
(j) Other Non Current Assets	7.51	10.02
Total Non-Current Assets	2,865.87	2,260.73
2. Current Assets		
(a) Inventories	1,422.32	1,271.35
(b) Financial Assets		
(i) Loans	288.66	234.74
(ii) Trade Receivable	1,563.03	1,332.64
(iii) Cash and Cash Equivalants	136.74	346.63
(iv) Bank Balances other than (iii) of above	Nil	Nil
(vi) Investments	Nil	312.30
(c) Current Tax Assets (Net)	180.94	301.41
(d) Other Current Assets	Nil	Nil
	3,591.69	3,799.08
(e) Assets Classified as held for Sales	Nil	Nil
Total Current Assets	3,591.69	3,799.08
TOTAL ASSETS	6,457.56	6,059.80
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	1,000.64	1,000.64
(b) Other Equity		
(i) Equity Component of Compound Financial Instrument	Nil	Nil
(ii) Other Comprehensive Income	(15.70)	(15.70)
(iii) Reserve and Surplus	4,373.75	4,015.38
(iv) Other Reserves	Nil	Nil
	4,358.05	3,999.67
	5,358.70	5,000.32



www.ganeshremedies.com
WEBSITE

contact@ganeshremedies.com | EMAIL

2. Liabilities		
(A) Non Current Liabilities	Nil	Nil
(a) Financial Liabilities		
(i) Borrowings	Nil	Nil
(ii) Trade payable	Nil	Nil
(iii) Other Financial Liabilities	Nil	Nil
(b) Provisions	18.08	16.81
(c) Deferred Tax Liabilities (Net)	22.23	23.90
(d) Other Non Current liabilities	Nil	Nil
Total Non Current Liabilities	40.31	40.71
(B) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	102.51	17.32
(ii) Trade Payable	730.89	620.77
(iii) Other Financial Liabilities	Nil	Nil
(b) Other Current Liabilities	Nil	4.15
(c) Provisions	40.97	53.38
(d) Current Tax Liabilities (Net)	184.19	323.16
Total Current Liabilities	1,058.56	1,018.78
Total Liabilities	1,098.87	1,059.49
TOTAL EQUITY AND LIABILITIES	6,457.56	6,059.80

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806



Ankleshwar
27th October 2021

Cash Flow Statement OF STANDALONE FINANCIAL STATEMENTS FOR THE YEAR ENDED

ALL AMOUNTS IN INDIAN RUPEES (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30 SEPTEMBER 2021 (Unaudited)	AS AT 31 MARCH 2021 (Audited)
Profit as Per Profit & Loss Account	718.19	1,294.95
Cash Flows from Operating Activities		
Non Cash Items	-	
Depreciation and Amortisations	167.52	272.54
Amortization of Land	9.41	6.19
Non Cash income or Exps	(888.42)	(1,062.46)
Change in Working Capital		
Decrease /Increase in Provison	(330.56)	15.88
Decrease / Increase in Debit balance of duties	(46.80)	76.55
Increase/ (Decrease) in Creditor	(2,742.06)	44.86
Decrease / Increase in Inventory	65.41	(720.93)
Increase / Decrease in Loan & Advances	(501.10)	73.03
Increase / Decrease in Debtors	2,936.00	330.54
Net Cash provided by operating activities	(612.41)	331.15
Cash Flows from Investing Activities		
Investment in Mutual Fund	314.67	(100.00)
Investments	(0.74)	(1.72)
Deposit	(9.70)	8.40
Fixed Assets	-	(0.90)
Net Cash provided by Investing Activities	304.23	(94.22)
Cash Flows from Financing Activities		
Issue of Shares under IPO	-	-
Mis. Assets	-	5.00
Secured Loans	(4.22)	(20.90)
Unsecured Loans	-	(49.79)
Security Premium	-	-
Net Cash provided by Financing Activities	(4.22)	(65.69)
Net increase / decrease in cash and cash equivalents	(312.40)	171.24
Cash and Cash equivalents at the beginning of the period	346.63	175.39
Cash and Cash equivalents at the end of the period	34.23	346.63

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806



Ankleshwar
27th October 2021

Notes to the Balance Sheet | Profit and loss account

ALL AMOUNTS IN LAKHS (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

NOTES

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on October 27, 2021 and reviewed by the Statutory Auditors of the company.
- 2 The Company had adopted Indian Accounting Standards (IND AS) notified by Ministry of Corporate Affairs with Effect from 1st April 2017. Financial results for the quarter and the six month ended on 30th Sep 2021 and quarter ended 30th June 2021 have been prepared accordingly. Financial Results for the quarter ended on 30th Sep 2020 have also been prepared in accordance with IND AS and are restated. The IND AS compliant results for the quarter and six month ended on 30th September 2020 have not been audited by the statutory auditors and provided their limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide true and fair view of the Company's affairs.
- 3 As required under Regulation 33 of SEBI (LODR) Regulations, 2015 the limited review by the statutory auditors have been completed for the quarter ended on 30th Sept 2021. The report does not have any impact on the above results and notes which needs explanation. The above results have been reviewed and recommended by the Audit Committee on 27th October 2021 and subsequently approved by the Board of Directors at its meeting held on 27th October 2021.
- 4 Earning per shares: Earning per shares are has been calculated on the weighted average of the share capital outstanding during the year. Half year EPS is not annualised.
- 5 The board has proposed a bonus issue in the ratio of 5:1 which constitutes a material event occurring after the balance sheet date. However, the effect thereof is not given on the Earning per share.
- 6 During current reporting period, on account of increase in the fuel prices, there has been a marginal increase in the cost of production by around 1.07% as compared to the previous reporting period.
- 7 The Company elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) ordinance, 2019. Accordingly, the Company had recognized the provision for income tax for the quarter and six month ended on 30th Septmber 2021 and 30th Septmber 2020 and re-measured its deferred tax basis the rate prescribed in the said section.
- 8 Previous year / Period figures have been re-grouped, re-arranged wherever considered necessary
- 9 The company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting"

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806
Ankleshwar
27th October 2021





RUSHIK J PATEL & CO.

CHARTERED ACCOUNTANT

Address: 2c to 2g, 2nd Floor, Resham Bhavan, Nr. Param Doctor House, Lal Darwaja, Surat
Email: mr.rushik@ymail.com Mo. No.8866288229

Independent Auditors' Review Report Consolidated Financial Results

ALL AMOUNTS IN INDIAN RUPEES (₹), IN LACS EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

To,
The Board Of Directors,
M/s Shree Ganesh Remedies Limited

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of M/s Shree Ganesh Remedies Limited ("the Company") for the period ended on 30th September 2021 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (as amended), including relevant circulars issued by the SEBI from time to time.

The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section -133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, read with the Circular is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Rushik J Patel & Co.
Chartered Accountants

Rushik J Patel
Proprietor

Membership No.148969
F.R.No.135751W

Date: 27th October 2021


UDIN 21148969AAAAEJ5865



STATEMENT OF CONSOLIDATED FINANCIAL STATEMENTS FOR THE QUARTER ENDED ON 30TH SEPTEMBER 2021

ALL AMOUNTS IN LAKHS (₹), EXCEPT EPS							
Particulars	Sr. No	Quarter Ended			Half year ended		Annual
		30th Sep 2021	30th June 2021	30th Sept 2020	30th Sept 2021	30th Sept 2020	31st Mar 2021
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
INCOME							
Revenue from operations	I	1,696.94	1,263.26	1,152.33	2,960.20	2,044.77	4,908.23
Other Income	II	43.98	110.83	45.41	154.81	140.88	209.43
Total Income (I+II)	III	1,740.92	1,374.09	1,197.74	3,115.01	2,185.65	5,117.66
EXPENSES							
Cost of Material Consumed	IV	892.11	760.27	558.99	1,652.37	1,008.85	2,598.56
Purchase of Stock in trade		Nil	Nil	Nil	Nil	Nil	Nil
Changes in inventories of finished goods/ WIP		(0.12)	(143.41)	(166.69)	(143.53)	(87.08)	(396.73)
Employee Benefit Expense		106.03	101.05	98.48	207.08	175.66	384.69
Finance Costs		2.76	6.97	1.15	9.73	3.48	6.77
Depreciation and Amortisations		95.39	81.53	63.84	176.92	127.68	272.54
Other Expenses		254.46	239.79	240.77	494.24	414.62	956.89
Total Expenses		1,350.62	1,046.20	796.53	2,396.82	1,643.21	3,822.71
Profit before exceptional, Extraordinary Item and tax (III - IV)	V	390.29	327.89	401.21	718.19	542.44	1,294.95
Exceptional Items	VI	Nil	Nil	Nil	Nil	Nil	Nil
Profit before Extraordinary Item and tax (V - VI)	VII	390.29	327.89	401.21	718.19	542.44	1,294.95
Extraordinary Items	VIII	Nil	Nil	Nil	Nil	Nil	Nil
Profit before tax (VII - VIII)	IX	390.29	327.89	401.21	718.19	542.44	1,294.95
Tax Expenses	X						
Current Tax		89.84	94.35	85.54	184.19	141.35	323.16
Adjustment of Tax Related to Earlier Periods		Nil	Nil	Nil	Nil	Nil	Nil
Deferred Tax		(1.40)	(0.27)	6.22	(1.67)	6.22	(3.63)
Profit/(loss) from continuing operations (IX - X)	XI	301.85	233.82	309.45	535.67	394.87	975.42
DISCONTINUING OPERATIONS							
Profit/(loss) from discontinuing operations before tax	XII	Nil	Nil	Nil	Nil	Nil	Nil
Tax expense of discontinuing operations	XIII	Nil	Nil	Nil	Nil	Nil	Nil
Profit/(loss) from discontinuing operations after tax (XII - XIII)	XIV	Nil	Nil	Nil	Nil	Nil	Nil
TOTAL OPERATIONS							
Profit (Loss) for the period (XI + XIV)	XV	301.85	233.82	309.45	535.67	394.87	975.42
OTHER COMPREHENSIVE INCOME							
Income relating to Item that will not be classified to profit and loss		Nil	Nil	Nil	Nil	Nil	Nil
Income relating to Item that will be classified to profit and loss		Nil	Nil	Nil	Nil	Nil	Nil
Total Comprehensive Income for the period		301.85	233.82	309.45	535.67	394.87	975.42
Total profit or loss, attributable to							
Profit or loss, attributable to owners of parent		Nil	Nil	Nil	Nil	Nil	Nil
Total profit or loss, attributable to non-controlling interests		Nil	Nil	Nil	Nil	Nil	Nil
Paid Up Equity Share Capital (Face Value Rs.10 each)		1,001	1,000.64	1,000.64	1,000.64	1,000.64	1,000.64
Other Equity Excluding Revaluation Reserves		Nil	Nil	Nil	Nil	Nil	3,999.67
Earning Per Share for Continuing operation							
Basic - Par Value Rs.10		3.02	2.34	3.09	5.35	3.95	9.75
Diluted - Par Value Rs.10		3.02	2.34	3.09	5.35	3.95	9.75

For, Shree Ganesh Remedies Limited


Chandul Kothia
Chairman and Managing Director
DIN NO - 00652806
Ankleshwar
27th October 2021



Balance Sheet OF CONSOLIDATED FINANCIAL STATEMENTS OF SHREE GANESH REMEDIES AND DHARI CHEMICALS LTD & AKSHAR JYOT PVT LTD FOR THE YEAR ENDED

ALL AMOUNTS IN INDIAN RUPEES (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30TH SEPTEMBER 2021 (Unaudited)	AS AT 31 MARCH 2021 (Audited)
ASSETS		
1. Non-Current Assets		
(a) Property, Plant and Equipments	2,552.54	1,824.64
(b) Capital work in progress	85.88	204.83
(c) Investment property	Nil	Nil
(d) Goodwill	Nil	Nil
(e) Other Intangible Assets	49.67	60.49
(f) Intangible Assets under development	Nil	Nil
(g) Biological Assets other than bearer Plant	Nil	Nil
(h) Financial Assets		
(i) Investments	7.00	7.00
(iii) Loans	161.53	153.75
(j) Deferred Tax Assets (Net)	Nil	Nil
(j) Other Non Current Assets	7.61	10.02
Total Non-Current Assets	2,864.23	2,260.73
2. Current Assets		
(a) Inventories	1,422.32	1,271.35
(b) Financial Assets		
(i) Loans	290.66	234.74
(ii) Trade Receivable	1,563.03	1,332.64
(iii) Cash and Cash Equivalants	145.80	346.63
(iv) Bank Balances other than (iii) of above	Nil	Nil
(vi) Investments	Nil	312.30
(c) Current Tax Assets (Net)	181.80	301.41
(d) Other Current Assets	Nil	Nil
	3,603.61	3,799.08
(e) Assets Classified as held for Sales	Nil	Nil
Total Current Assets	3,603.61	3,799.08
TOTAL ASSETS	6,467.84	6,059.80
EQUITY AND LIABILITIES		
1. Equity		
(a) Equity Share Capital	1,000.64	1,000.64
(b) Other Equity		
(i) Equity Component of Compound Financial Instrument	Nil	Nil
(ii) Other Comprehensive Income	(15.70)	(15.70)
(iii) Reserve and Surplus	4,373.75	4,015.38
(iv) Other Reserves	Nil	Nil
	4,358.05	3,999.67
	5,358.70	5,000.32

2. Liabilities		
(A) Non Current Liabilities	Nil	Nil
(a) Financial Liabilities		
(i) Borrowings	Nil	Nil
(ii) Trade payable	Nil	Nil
(iii) Other Financial Liabilities	Nil	Nil
(b) Provisions	18.93	16.81
(c) Deferred Tax Liabilities (Net)	22.23	23.90
(d) Other Non Current liabilities	Nil	Nil
Total Non Current Liabilities	41.16	40.71
(B) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	111.93	17.32
(ii) Trade Payable	730.89	620.77
(iii) Other Financial Liabilities	Nil	Nil
(b) Other Current Liabilities	Nil	4.15
(c) Provisions	40.97	53.38
(d) Current Tax Liabilities (Net)	184.19	323.16
Total Current Liabilities	1,067.98	1,018.78
Total Liabilities	1,109.15	1,059.49
TOTAL EQUITY AND LIABILITIES	6,467.84	6,059.80

For, Shree Ganesh Remedies Limited



Chandulal Kothia

Chairman and Managing Director

DIN NO - 00652806



Ankleshwar


27th October 2021

Cash Flow Statement OF CONSOLIDATED FINANCIAL STATEMENTS OF SHREE GANESH REMEDIES AND DHARI CHEMICALS LTD & AKSHAR JYOT PVT LTD FOR THE YEAR ENDED

ALL AMOUNTS IN INDIAN RUPEES (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

	AS AT 30 SEPTEMBER 2021 (Unaudited)	AS AT 31 MARCH 2021 (Audited)
Profit as Per Profit & Loss Account	718.19	1,294.95
Cash Flows from Operating Activities		
Non Cash Items		
Depreciation and Amortisations	167.52	272.54
Amortization of Land	9.41	6.19
Non Cash income or Exps	(888.42)	(1,062.46)
Change in Working Capital		
Decrease /Increase in Provison	(330.56)	15.88
Decrease / Increase in Debit balance of duties	(46.80)	76.55
Increase/ (Decrease) in Creditor	(2,742.06)	44.86
Increase/ (Decrease) in Creditor - DCL	(18.59)	-
Increase/ (Decrease) in Creditor - AJPL	(0.01)	-
Decrease / Increase in Inventory	65.41	(720.93)
Increase / Decrease in Loan & Advances	(500.78)	73.03
Increase / Decrease in Loan & Advances - AJPL	7.79	-
Increase / Decrease in Loan & Advances - DCL	(2.33)	-
Increase / Decrease in Debtors	2,936.00	330.54
Net Cash provided by operating activities	(625.22)	331.15
Cash Flows from Investing Activities		
Investment in Mutual Fund	314.67	(100.00)
Investments	(0.74)	(1.72)
Investments - DCL	(346.91)	-
Investments - AJPL	(0.26)	-
Deposit	(9.70)	8.40
Fixed Assets	-	(0.90)
Net Cash provided by Investing Activities	(42.94)	(94.22)
Cash Flows from Financing Activities		
Capital Issue - DCL	1.00	-
Capital Issue - AJPL	1.00	-
Mis. Assets	-	5.00
Secured Loans	(4.22)	(20.90)
Unsecured Loans - SGRL	-	(49.79)
Unsecured Loans - AJPL	(7.75)	-
Unsecured Loans - DCL	374.79	-
Net Cash provided by Financing Activities	364.83	(65.69)
Net increase / decrease in cash and cash equivalents	(303.34)	171.24
Cash and Cash equivalents at the beginning of the period	346.63	175.39
Cash and Cash equivalents at the end of the period	43.29	346.63

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806
Ankleshwar
27th October 2021



Notes to the Consolidated Balance Sheet | Profit and loss account

ALL AMOUNTS IN LAKHS (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

NOTES

- 1 The above consolidated results have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on October 27, 2021 and reviewed by the Statutory Auditors of the company.
- 2 The Company had adopted Indian Accounting Standards (IND AS) notified by Ministry of Corporate Affairs with Effect from 1st April 2017. Financial results for the quarter and the six month ended on 30th Sep 2021 and quarter ended 30th June 2021 have been prepared accordingly. Financial Results for the quarter ended on 30th Sep 2020 have also been prepared in accordance with IND AS and are restated. The IND AS compliant results for the quarter and six month ended on 30th September 2020 have not been audited by the statutory auditors and provided their limited review. However, the management has exercised necessary due diligence to ensure that the financial results provide true and fair view of the Company's affairs.
- 3 Earning per shares: Earning per shares are has been calculated on the weighted average of the share capital outstanding during the year. Half year EPS is not annualised.
- 4 The board has proposed a bonus issue in the ratio of 5:1 which constitutes a material event occurring after the balance sheet date. However, the effect thereof is not given on the Earning per share.
- 5 The Company elected to exercise the option permitted under Section 115BAA of the Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) ordinance, 2019. Accordingly, the Company had recognized the provision for income tax for the quarter and six month ended on 30th September 2021 and 30th September 2020 and re-measured its deferred tax basis the rate prescribed in the said section.
- 6 Previous year / Period figures have been re-grouped, re-arranged wherever considered necessary
- 7 The company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting"

For, Shree Ganesh Remedies Limited


Chandulal Kothia
Chairman and Managing Director
DIN NO - 00652806
Ankleshwar
27th October 2021

